At the present time, there are over 2000 MicroRNA (miRNAs) discovered in humans that helps in the regulation of gene expression. Most of the human disease occurs due to genetic changes, therefore miRNA is considered to be key element of clinical diagnostics and therapeutic agents. Mostly the MicroRNA (miRNA)-based therapeutics can be further categorised or segmented into miRNA mimics and inhibitors of miRNAs (antimiRs). As, miR-34a is a miRNA mimic which majorly aims the BCL2, MET, MYC, CDK6, and other genetic factor for the treatment of compact tumours such as lung, liver, colon, brain, bladder, prostate, pancreases, and others.
According to the report
analysis, ‘MicroRNA (miRNAs) Market: Current Analysis and
Forecast (2021-2027)’ states that some of the major players
operating in the market include Merck KGaA, Thermo Fisher Scientific, Inc.,
Horizon Discovery Ltd., Synlogic, QIAGEN, GeneCopoeia, Inc., New England
Biolabs, Quantabio, NanoString, BioGenex, and many more which have been covered
in the report at the various level with multiple cross comparisons and product
and services offered along with partnerships which have been commenced by these
players to enhance their existence in different regions.
Major factors which are influencing the market includes the demand
for miRNA is mainly increasing on account of the emerging microRNA (miRNA)
tools for disease-associated applications, the high impact of miRNA in the
target observation and forecast, also the heavy adoption of miRNA by way of a impending
biomarker. On the other hand, overexpressed miRNA in few of the illnesses can
be also called as generally oncogenes, however under expressed miRNA in few of
the illness can be also called as a tumour suppressor miRNA.
The market adoption of miRNA is analysed based on its worldwide
presence in the countries such as North America (United States, Canada, and Other
region of North America), Europe (France, Germany, United Kingdom Italy, Spain,
and Other regions of Europe), Asia-Pacific (China, India, Australia, Japan, and
other regions of APAC), and other part of the World. It has been anticipated
that the North America will dominate the miRNA market majorly owing to the
rising digit of clinical trials for the expansion of unique therapeutics, and
the rising launches of the fresh new products in the region. Also in recent
times, some of the company’s like amgen and arrowhead pharmaceuticals has
entered into an agreement between the two for licensing and collaboration for
the deals to improve miRNA-based therapies majorly for cardiac ailments.
In the near future, report also predicts that the MicroRNA (miRNAs) market
will increase at a significant CAGR during the period 2021 – 2027 majorly due
to increasing mergers and acquisitions of the companies in the market coupled
with increasing number of product launches by the companies to achieve higher
penetration into the market.
For More Information, refer to
below link:-
Global
MicroRNA (miRNAs) Market
Follow Us:-
LinkedIn | Instagram | Facebook | Twitter | YouTube
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Support@kenresearch.com
+91-9015378249
